Media headlines about PRA Health Sciences (NASDAQ:PRAH) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PRA Health Sciences earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.1392962504369 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of brokerages recently commented on PRAH. Zacks Investment Research downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday. SunTrust Banks reiterated a “buy” rating and set a $101.00 price objective on shares of PRA Health Sciences in a research report on Friday, October 27th. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. Barclays began coverage on PRA Health Sciences in a research report on Monday, December 11th. They set an “overweight” rating and a $94.00 price objective on the stock. Finally, Mizuho began coverage on PRA Health Sciences in a research report on Thursday, September 21st. They set a “buy” rating and a $82.00 price objective on the stock. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $92.00.
PRA Health Sciences (PRAH) traded down $1.28 during mid-day trading on Friday, reaching $90.06. The company’s stock had a trading volume of 353,127 shares, compared to its average volume of 443,678. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01. The firm has a market capitalization of $5,790.00, a PE ratio of 50.60, a price-to-earnings-growth ratio of 1.27 and a beta of 0.41. PRA Health Sciences has a one year low of $54.08 and a one year high of $92.84.
PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million during the quarter, compared to analysts’ expectations of $477.89 million. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.64 earnings per share. analysts predict that PRA Health Sciences will post 3.2 EPS for the current fiscal year.
In other PRA Health Sciences news, Director Matthew P. Young sold 5,115 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David W. Dockhorn sold 72,850 shares of the firm’s stock in a transaction on Friday, December 28th. The stock was sold at an average price of $90.83, for a total value of $6,616,965.50. Following the sale, the executive vice president now directly owns 72,850 shares of the company’s stock, valued at approximately $6,616,965.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 150,815 shares of company stock valued at $13,642,620. 2.10% of the stock is owned by insiders.
WARNING: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://ledgergazette.com/2018/01/12/pra-health-sciences-prah-earning-somewhat-favorable-news-coverage-accern-reports.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.